Who are Gemzar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cladribine Tablets, Gemcitabine Injectable Product, Cladribine Pill, Gemcitabine Hydrochloride Injection, Gemcitabine monotherapy, CEDAZURIDINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gemzar — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemzar (Gemcitabine Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside metabolic inhibitor. Area: Oncology.

marketed Nucleoside metabolic inhibitor Ribonucleotide reductase; DNA incorporation Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemzar (Gemcitabine Hydrochloride) — Accord Hlthcare. Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gemzar TARGET	Gemcitabine Hydrochloride	Accord Hlthcare	marketed	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
Cladribine Tablets	Cladribine Tablets	Keith Edwards, M.D.	marketed	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation
Gemcitabine Injectable Product	Gemcitabine Injectable Product	Henan Cancer Hospital	marketed	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA incorporation
Cladribine Pill	Cladribine Pill	Haukeland University Hospital	phase 3	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation
Gemcitabine Hydrochloride Injection	Gemcitabine Hydrochloride Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA incorporation
Gemcitabine monotherapy	Gemcitabine monotherapy	AstraZeneca	phase 3	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA incorporation
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-06-28 — Gemzar · 12403086 · Formulation · US
2032-04-15 — Gemzar · 8679094 · Formulation · US
2033-07-01 — Gemzar · 9241948 · Formulation · US
2034-08-19 — Gemzar · 10729823 · Formulation · US
2034-08-19 — Gemzar · 12447241 · Formulation · US

Sponsor landscape (Nucleoside metabolic inhibitor class)

Accord Hlthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemzar — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab